These biotech stocks are getting hammered by shocking brittle-bone treatment study results | Curated by Alerts360
Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab. Stay informed with the latest market updates, stock movements, and financial news to make timely decisions.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
